Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis

Nat Nanotechnol. 2023 Jun;18(6):617-627. doi: 10.1038/s41565-023-01346-x. Epub 2023 Mar 27.


Inflammatory bowel disease can be caused by the dysfunction of the intestinal mucosal barrier and dysregulation of gut microbiota. Traditional treatments use drugs to manage inflammation with possible probiotic therapy as an adjuvant. However, current standard practices often suffer from metabolic instability, limited targeting and result in unsatisfactory therapeutic outcomes. Here we report on artificial-enzyme-modified Bifidobacterium longum probiotics for reshaping a healthy immune system in inflammatory bowel disease. Probiotics can promote the targeting and retention of the biocompatible artificial enzymes to persistently scavenge elevated reactive oxygen species and alleviate inflammatory factors. The reduced inflammation caused by artificial enzymes improves bacterial viability to rapidly reshape the intestinal barrier functions and restore the gut microbiota. The therapeutic effects are demonstrated in murine and canine models and show superior outcomes to traditional clinical drugs.

MeSH terms

  • Animals
  • Bifidobacterium longum*
  • Dogs
  • Dysbiosis / therapy
  • Inflammation / drug therapy
  • Inflammatory Bowel Diseases* / drug therapy
  • Mice
  • Microbiota*
  • Probiotics* / pharmacology
  • Probiotics* / therapeutic use